Immunohistochemical Analysis of p63 Marker Expression in Pleomorphic Adenoma and Mucoepidermoid Carcinoma of Salivary Gland

Document Type : Original Article

Authors

1 Associate Professor of Periodontology. Department of Periodontology. Dental School, Jundishapour University of Medical Sciences, Ahvaz, Iran.

2 Assistant Professor of Health Nutrition.Department of Health Nutrition, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Iran.

3 Assistant Professor of Pathology.Department of Pathology, jundishapour University of Medical Sciences, Ahvaz, Iran.

4 Dental Students.Dental Students, Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abstract

Background and Objective: Tumors of salivary gland represent 2-3% of head and neck neoplasms and little is known about the underlying molecular mechanisms leading to tumorigenesis. P63 plays an essential role in epithelial development, stem cell identity and cellular differentiation and may act as an oncogene. The expression of P63 was analyzed to investigate the role of this marker in tumorigenesis of salivary gland neoplasms.
Subjects and Methods: In this study, tissue specimens of 18 pleomorphic denoma (PA) and 9 mucoepidermoid carcinoma (MEC) were examined by immunohistochemistry for p63 expression. The percentage of positive neoplastic cells was calculated from a minimum of 1000 cells.
Results: In normal salivary gland and PA, P63 was expressed in myoepithelial and basal duct cells, whereas ductal and acinus cells were always negative. In MEC, intermediate and epidermoid cells expressed p63, in contrast to mucous cells. After using statistical test, the percentage of p63 positive cells in MEC was 84.44% and in PA was 57.83% (p<0.05).
Conclusion: p63 is expressed in the nuclei of normal salivary gland myoepithelial and basal cells. P63 expression is retained in the epidermoid cells of MEC and myoepithelial and basal cells of PA, which suggests a role of p63 in oncogenesis of these tumors.
 

Keywords

References

1-AL-Rawi NH, Omer H, AL Kawas S. Immunohistochemical analysis of P(53) an bcl-2 in benign and malignant salivary glands tumors.  J Oral Pathol Med 2010;39(1):48-55.
2-Kumamoto H, Ohki K, Ooya K. Expression of p63 and p73 in ameloblastomas. J Oral Pathol Med 2005; 34(4):220-6.
3-Sengüven B, Oygür T. Investigation of interleukin-1 alpha and interleukin-6 expression and interleukin-1 alpha gene polymorphism in keratocystic odontogenic tumors and ameloblastomas. Med Oral Patol Oral Cir Bucal 2011;16:e467-72.
4-Vered M, Allon I, Dayan D. Maspin, p53, p63 and Ki-67 in epithelial lesions of the tongue: from hyperplasia through dysplasia to carcinoma. J Oral Pathol Med 2009; 38(3): 314-20.
5-Xavier FC, Takiya CM, Reis SR, Ramalho LM. P63 Immunoexpression in lip carcinogenesis. J Mol Histol 2009; 40(2):131-7.
6-Lo Muzio L, Santarelli A, Caltabiano R, Rubini C, Pieramici T, Fior A, etal.  P63 expression in odontogenic cysts. Int J Oral Maxillofac Surg 2005;34(6):668-73.
7-Morais Mde L, Azevedo PR, Carvalho CH, Medeiros L, Lajus T, Costa Ade L. Clinicopathological study of salivary gland tumors: an assessment of 303 patients. Cad Saude Publica 2011;27(5):1035- 40.
8-Ito FA, Jorge J, Vargas PA, Lopes MA. Histopathological findings of pleomorphic adenomas of the salivary gland. Med Oral Patol Oral Cir Bucal 2009;14(2): E 57- 61.
9-Bilal H, Handra-Luca A, Bertrand JC, Fouret PJ. P63 is expressed in basal and myoepithelial cells of human normal and tumor salivary gland tissues. J Histochem Cytochem 2003;51(2):133-9.
10-Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. P63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157(6):1769– 75.
11-Mitani Y, Li J, Weber RS, Lippman SL, Flores ER, Caulin C, et al. Expression and regulation of the ΔN and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings. Am J Pathol 2011;179(1):391- 9.
12-Emanuel P, Wang B, Wu M, Burstein DE. P63 Immunohistochemistery in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma. Mod  Pathol 2005;18(5):645-50.
13-Weber A, Langhanki L, Schutz A, Gerstner A, Bootz F, Wittekind C, et al. Expression profiles of p53, p63, and p73 in benign salivary gland tumors. Virchows Arch 2002;441(5):428-36.
14-Ramer N, Wu H, Sabo E, Ramer Y, Emanuel P, Orta L, et al. Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis. Cancer 2010;116(1):77-83.
15-Genelhu MC, Gobbi H, Soares FA, Campos AH, Ribeiro CA, Cassali GD. Immunohistochemical expression of p63 in pleomorphic adenomas and carcinomas ex-pleomorphic adenomas of salivary glands. Oral Oncol 2006;42(2):154-60.
16-Foschini MP, Gaiba A, Cocchi R, Pennesi MG, Pession A. P63 expression in salivary gland tumors: role of DeltaNp73L in neoplastic transformation. Int J Surg Pathol 2005; 13(4):329-35.
17 Maruya S, Kies MS, Williams M, Myers JN, Weber RS, Batsakis JG et al. Differential expression of p63 isotypes (DeltaN and TA) in salivary gland neoplasms: biological and diagnostic implications. Hum Pathol 2005;36(7):821-7.
18-McHugh JB, Hoschar AP, Dvorakova M, Parwani AV, Barnes EL, Seethala RR. P63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma. Head Neck Pathol 2007;1(2):123-31.
19-Kawahara A, Harada H, Yokoyama T, Kage M. P63 Expression of clear myoepithelial cells in epithelial-myoepithelial carcinoma of the salivary gland: a useful marker for naked myoepithelial cells in cytology. Cancer 2005;105(4):240-5.
20-Seethala RR, LiVolsi VA, Zhang PJ, Pasha TL, Baloch ZW. Comparison of p63 and p73 expression in benign and malignant salivary gland lesions. Head Neck 2005;27(8):696-702.
Jundishapur Scientific Medical Journal
Volume 11, Issue 5
July and August 2017
Pages 541-548

Files

History

  • Receive Date: 12 April 2012
  • Revise Date: 17 June 2012
  • Accept Date: 25 June 2012

Share

How to cite

Statistics